+Compare
MDGL
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
3.9B

MDGL Price Prediction, Madrigal Pharmaceuticals AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MDGL with price predictions
07:00 PM EST Nov 29, 2023

MDGL in upward trend: price rose above 50-day moving average on November 14, 2023

MDGL moved above its 50-day moving average on November 14, 2023 date and that indicates a change from a downward trend to an upward trend. In of 53 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 01, 2023. You may want to consider a long position or call options on MDGL as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MDGL just turned positive on October 30, 2023. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for MDGL crossed bullishly above the 50-day moving average on November 16, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 165 cases where MDGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MDGL broke above its upper Bollinger Band on November 16, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MDGL's P/B Ratio (169.492) is slightly higher than the industry average of (20.643). P/E Ratio (0.000) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.009).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

MDGL is expected to report earnings to -532 cents per share on February 22

Madrigal Pharmaceuticals MDGL Stock Earnings Reports
Q4'23
Est.
$-5.33
Q3'23
Missed
by $0.44
Q2'23
Missed
by $0.10
Q1'23
Beat
by $0.73
Q4'22
Missed
by $0.35
The last earnings report on November 06 showed earnings per share of -534 cents, missing the estimate of -490 cents. With 153.12K shares outstanding, the current market capitalization sits at 3.90B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 27%, and the average quarterly price growth was 20%. AMPE experienced the highest price growth at 177%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was 23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
200 Barr Harbor Drive
Phone
+1 267 824-2827
Employees
92
Web
http://www.madrigalpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TYG28.130.22
+0.79%
Tortoise Energy Infrastructure Corp
SDVY29.430.16
+0.55%
First Trust SMID Cp Rising Div Achv ETF
HYGI25.52N/A
N/A
iShares Inflation Hedged Hgh Yld Bd ETF
OAEM28.36-0.16
-0.58%
OneAscent Emerging Markets ETF
SBI7.48-0.08
-1.06%
Western Asset Intermediate Muni Fund

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with VKTX. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+3.01%
VKTX - MDGL
63%
Loosely correlated
+3.30%
SGMO - MDGL
62%
Loosely correlated
+4.57%
IBRX - MDGL
62%
Loosely correlated
-7.54%
KA - MDGL
62%
Loosely correlated
+13.43%
RVMD - MDGL
61%
Loosely correlated
+3.87%
More